SLOUGH, England and RICHMOND, Va., July 27, 2018 /PRNewswire/ — Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved Perseris, the first once-monthly subcutaneous risperidone-containing, long-acting…Original Article
FDA Approves Perseris (risperidone) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
